Who Supplies Vitamin to India from GAMBIA

To import finished pharmaceutical formulations containing vitamins into India, the Central Drugs Standard Control Organization (CDSCO) mandates that both the manufacturing site and the products be registered. The process involves obtaining an Import Registration Certificate and an Import License from CDSCO. The application must include comprehensive documentation such as the Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The registration timeline can vary, but it typically ranges from 6 to 12 months, depending on the completeness of the application and the regulatory workload. For products under HS Code 30049099, which covers medicaments consisting of mixed or unmixed products for therapeutic or prophylactic uses, the registration process is stringent to ensure safety, efficacy, and quality. Additionally, an Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT) is required to facilitate the import process.

Imported finished pharmaceutical formulations containing vitamins must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, adhering to International Council for Harmonisation (ICH) guidelines for Zone IV, is necessary to demonstrate the product's shelf-life under Indian climatic conditions. Upon arrival, customs drug inspectors conduct port inspections to verify the authenticity and quality of the products. If a batch fails to meet the required standards, it may be rejected, leading to potential financial losses and reputational damage for the importer.

Between 2024 and 2026, CDSCO has implemented stricter regulations for the import of pharmaceutical products, including mandatory import registration and licensing. These measures aim to prevent the sale of unapproved or illegal medicines in the Indian market. The introduction of the Production Linked Incentive (PLI) scheme has also impacted the import of finished formulations, encouraging domestic manufacturing and reducing dependency on imports. While the PLI scheme offers incentives for domestic production, it has led to a more competitive environment, affecting the volume of imports from countries like Gambia.

India's demand for finished vitamin formulations is driven by the need for specialized dosage forms, patented or branded products, and formulations not readily available domestically. The market size for vitamin formulations in India is substantial, with a total export market of $143.4 million across 1,222 exporters to 172 countries. This indicates a robust demand for both domestic and imported vitamin formulations. The import of finished formulations allows Indian consumers access to a wider range of products, including those with unique delivery mechanisms or novel combinations not produced locally.

The Basic Customs Duty (BCD) for products under HS Code 30049099 is 10%. Additionally, a Social Welfare Surcharge (SWS) of 10% is applied on the BCD, effectively making the total duty 11%. The Goods and Services Tax (GST) at 12% is levied on the total value, including the customs duty. Therefore, the total landed duty percentage is approximately 23.536%. These duties are subject to change based on government policies and international trade agreements.

India sources finished vitamin formulations from Gambia due to specific formulations that may not be readily available from other suppliers. Gambia's share in India's total vitamin formulation imports is relatively small, but it provides unique products that cater to niche market segments. Other major suppliers include China, Germany, and the United States, which offer a broader range of products. Gambia's competitive advantage lies in its ability to supply specialized formulations that meet specific therapeutic needs, thereby complementing the offerings from other countries.

India imports finished vitamin formulations from Gambia to access specialized products not available domestically. These include unique dosage forms, patented formulations, and products that cater to specific therapeutic needs. Gambia's ability to supply such specialized formulations provides Indian consumers with a broader range of options, enhancing treatment outcomes.

Compared to major suppliers like China, Germany, and the United States, Gambia offers unique formulations that may not be readily available from these countries. While larger suppliers provide a broader range of products, Gambia's niche offerings cater to specific market segments, providing a competitive edge in those areas. Gambia's focus on quality and compliance with international standards further enhances its appeal as a sourcing destination.

Importing from Gambia presents certain risks, including potential regulatory changes, currency fluctuations, and shipping disruptions. However, the volume of imports is relatively low, mitigating the impact of any single disruption. Maintaining a diversified supplier base and establishing strong relationships with multiple suppliers can help Indian importers manage these risks effectively.

1. 1Dual-Sourcing: Engage with multiple suppliers to mitigate risks associated with single-source dependency.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against potential supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC) to ensure financial security.
4. 4Supplier Qualification: Conduct thorough due diligence to ensure suppliers meet quality and regulatory standards.
5. 5Regulatory Compliance: Stay updated on import regulations and ensure all necessary documentation is in place.

1. 1DGFT IEC: Obtain an Importer Exporter Code from the Directorate General of Foreign Trade.
2. 2CDSCO Form 40/41: Apply for the necessary import registration and license from CDSCO.
3. 3Drug Import License